Abstract
Blood group incompatibility between donor and recipient of allogeneic stem cell transplants may be associated with post-transplant erythroid aplasia. A total of 548 patients (pts) received allogeneic transplant for malignant and non-malignant hematologic disorders. In a retrospective analysis, the prevalence and outcome of pure red-cell aplasia (PRCA) in 44 pts with major and bi-directional ABO-mismatch were investigated. Bone marrow grafts were major ABO incompatible in 30 pts; there was bi-directional mismatch in the remaining 14 pts. The median number of transplanted mononuclear cells (NC) was 4.74 × 108/kg (range 0.1–26.4) including CD34+ cells, 3.02 × 106/kg (range 0.9–21.7). Granulocyte engraftment >0.5 × 10e9/l occurred after a median of 21 days (7–32), and platelet exceeded >50 × 10e9/l after a median of 23.5 days (12–109). Acute and chronic graft vs host disease (GVHD) developed in 23 (52%) and 26 (59%) of the patients, respectively. Six (13%) patients transplanted with major and bi-directional ABO-incompatibility developed PRCA. The treatment of PRCA consisted of plasmapheresis (PEX), rapid cyclosporine (CsA) discontinuation, donor lymphocyte infusions (DLI), erythropoietin (EPO), azathioprine, and rituximab. The therapy resulted in erythroid recovery in five out of six patients after a median of 13 months (range 3–16). The median number of transfused red blood cells (RBCs) was 36 U (range 8–57). With a median follow-up of 37 months, the 5-year probability of overall survival (OS) for the PRCA group was 66%. Major ABO mismatch may lead to delayed donor erythroid engraftment. It results in long-term transfusion dependence and, therefore, the risk of iron overload. The therapy is long lasting, but usually effective in majority of patients.
Similar content being viewed by others
References
Bavaro P, Di Girolamo G, Olioso P, Papalinetti G, Iacone A, Accorsi P, Di Bartolomeo (1999) Donor lymphocyte infusion as therapy for pure red cell aplasia following bone marrow transplantation. Br J Haematol 104(4):930–931
Bensinger WI, Buckner CD, Thomas ED, Clift RA (1982) ABO-incompatible marrow transplants. Transplantation 33:427–429
Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, Barrett J, Childs RW (2001) Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 98:1687–1694
Deotare UR, Vishwabandya A, Mathews V, George B, Srivastava A, Chandy M (2006) Response to high-dose dexamethasone for acquired pure red cell aplasia following ABO-mismatched allogeneic stem cell transplantation. Bone Marrow Transplant 37:1149–1150
Gmur J, Burger J, Schaffner A, Neftel K, Oelz O, Frey D, Metaxas M (1990) Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 75:290–295
Griffith LM, McCoy JP Jr, Bolan CD, Stroncek DF, Pickett AC, Linton GF, Lundqvist A, Srinivasan R, Leitman SF, Childs RW (2005) Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 128:668–675
Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, Wojnar J, Markiewicz M, Wojciechowska-Sadus M, Kopera M, Kruzel T, Najda J, Nowak K, Holowiecki J (2005) Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in 2 patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Haematologica 90(Suppl):ECR33
Hows JM, Chipping PM, Palmer S, Gordon-Smith EC (1983) Regeneration of peripheral blood cells following ABO incompatible allogeneic bone marrow transplantation for severe aplastic anaemia. Br J Haematol 53:145–151
Hyell A, Aul C, Runde V, Arning M, Schneider W, Wernet P (1991) Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation with recombinant erythropoietin. Blood 77:906
Lee JH, Lee KH, Kim S, Lee JS, Kim SH, Kwon SW, Kim WK (2000) Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 25:179–184
Lee JH, Lee JH, Choi SJ, Kim S, Soel M, Kwon SW, Park CJ, Chi HS, Lee JS, Kim WK, Lee KH (2003) Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 120:702–710
Maschan AA, Skorobogatova EV, Balsashov DN, Pashanov ED, Trakhtman PE, Schipitizina IP, Skvortsova YV, Rumiantzev AG (2002) Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant 30:405–407
Mehta J, Powles R, Horton C, Milan S, Singhal S, Treleaven J (1995) Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings. Bone Marrow Transplant 15:853–858
Mielcarek M, Leisenring W, Torok-Storb B, Storb R (2000) Graft-versus-host disease and donor-directed hemagglutinin titrem after ABO-mismatched related and unrelated marrow allografts: evidence for graft -versus-plasma cell effect. Blood 96:1150–1156
Or R, Naparstek E, Mani N, Slavin S (1991) Treatment of pure red cell aplasia following ABO-incompatible bone marrow transplantation: two case reports with successful response to plasmapheresis. Transpl Int 4:99–102
Paltiel O, Cournoyer D, Rybka W (1993) Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion 33:418–421
Pegs KS, Morris EC, Kottaridis PD, Geary J, Goldstone AH, Linch DC, Mackinnon S (2002) Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen. Blood 99:4642–4644
Rabitsch W, Knobl P, Prinz E, Keil F, Greinix H, Kahls P, Worel N, Jansen M, Horl WH, Derfler K (2003) Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb® immunoadsorption. Bone Marrow Transplant 32:1015–1019
Santamaria A, Sureda A, Martino R, Domingo-Albos A, Muniz-Diaz E, Brunet S (1997) Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant 12:1105–1107
Schetelig J, Breitschaft A, Kroger N, Zabelina T, Ebell W, Bornhauser M, Haack A, Ehninger G, Salama A, Siegert W (2005) After major ABO-mismatched allogeneic hematopoietic progenitor stem cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B. Transfusion 45:779
Seebach JD, Stussi G, Passweg JR, Loberiza FR Jr, Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Elfenbein GJ, Gale RP, van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, Klumpp TR, Horowitz MM, Ringden O, Barret AJ (2005) GVHD Working Committee of Center for International Blood and Marrow Transplant Research. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 11:1006–1013
Sora F, De Matteis S, Piccirillo N, Chiusolo P, Laurenti L, Putzulu R, Leone G, Sica S (2005) Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion 45:643–644
Verholen F, Stadler M, Helg C, Chalandon Y (2004) Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 73:441–446
Worel N, Greinix HT, Schneider B, Kurz M, Rabitsch W, Knobl P, Reiter E, Derfler K, Fischer G, Hintenberger W, Hocker P, Kahls P (2000) Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 40:543–550
Volin L, Ruutu T (1990) Pure red-cell aplasia of long duration after major ABO-incompatible bone marrow transplantation. Acta Haematol 84:195–197
Yang MH, Hsu HC (2001) Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anaemia with response to steroids: a case report and literature review. Ann Hematol 80:299–301
Zhu K, Chen J, Chen S (2005) Treatment of Epstein–Barr virus-associated lymphoproliferative disorder (EBV–PTLD) and pure red cell aplasia (PRCA) with rituximab following unrelated cord blood transplantation: a case report and literature review. Hematology 10:365–370
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Helbig, G., Stella-Holowiecka, B., Wojnar, J. et al. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. Ann Hematol 86, 677–683 (2007). https://doi.org/10.1007/s00277-007-0304-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-007-0304-8